Wall Street brokerages expect Viveve Medical, Inc. (NASDAQ:VIVE) to report sales of $3.29 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Viveve Medical’s earnings, with the lowest sales estimate coming in at $3.13 million and the highest estimate coming in at $3.57 million. Viveve Medical posted sales of $1.56 million during the same quarter last year, which would indicate a positive year over year growth rate of 110.9%. The company is scheduled to announce its next quarterly earnings results on Thursday, August 10th.

On average, analysts expect that Viveve Medical will report full-year sales of $3.29 million for the current fiscal year, with estimates ranging from $14.82 million to $16.00 million. For the next financial year, analysts anticipate that the firm will report sales of $25.00 million per share, with estimates ranging from $21.36 million to $28.20 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Viveve Medical.

Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.06. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $2.70 million. Viveve Medical had a negative net margin of 255.11% and a negative return on equity of 232.94%.

Several analysts have commented on VIVE shares. B. Riley reaffirmed a “buy” rating and set a $10.00 price objective on shares of Viveve Medical in a research note on Wednesday, May 17th. ValuEngine raised Viveve Medical from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Raymond James Financial, Inc. started coverage on Viveve Medical in a research note on Thursday, May 25th. They set an “outperform” rating and a $10.00 price objective for the company. Finally, Cowen and Company started coverage on Viveve Medical in a research note on Wednesday, May 3rd. They set an “outperform” rating and a $11.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.25.

A number of hedge funds have recently bought and sold shares of the stock. EcoR1 Capital LLC bought a new stake in Viveve Medical during the first quarter valued at approximately $1,583,000. Granahan Investment Management Inc. MA boosted its position in Viveve Medical by 8.0% in the first quarter. Granahan Investment Management Inc. MA now owns 396,494 shares of the company’s stock valued at $2,510,000 after buying an additional 29,364 shares during the last quarter. Wexford Capital LP boosted its position in Viveve Medical by 23.9% in the first quarter. Wexford Capital LP now owns 777,124 shares of the company’s stock valued at $4,919,000 after buying an additional 150,000 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Viveve Medical during the first quarter valued at about $5,942,000. Finally, HighTower Advisors LLC boosted its position in Viveve Medical by 36.9% in the first quarter. HighTower Advisors LLC now owns 1,293,718 shares of the company’s stock valued at $8,192,000 after buying an additional 348,682 shares during the last quarter. 60.85% of the stock is owned by hedge funds and other institutional investors.

Viveve Medical (NASDAQ VIVE) opened at 7.30 on Friday. The stock has a 50 day moving average price of $7.57 and a 200-day moving average price of $6.07. Viveve Medical has a one year low of $3.75 and a one year high of $11.16. The firm’s market capitalization is $141.28 million.

WARNING: “$3.29 Million in Sales Expected for Viveve Medical, Inc. (VIVE) This Quarter” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/07/09/3-29-million-in-sales-expected-for-viveve-medical-inc-vive-this-quarter-2.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.